Our latest conference coverage this week comes from Seattle, which is hosting the American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology event.

Yesterday’s sessions generated quite a few thoughts about some of the new directions the field is headed in, some of which may turn out to be more surprising than others.

While there were a few snippy comments and illusions flying around, there was also some interesting data being presented.

Here we take a look at one unexpected potential growth area, which might well throw some shade on allogeneic CARs…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by